Request for sample pages. Table of contents. 1. Report Introduction. 2. Acromegaly 2.1. Overview. 2.2. History 2.3. Acromegaly Symptoms. 2.4. Causes. 2.5.Pathophysiology. 2.6. Acromegaly Diagnosis 2.6.1. Diagnostic Guidelines. 3. Acromegaly Current Treatment Patterns. 3.1. Acromegaly Treatment Guidelines. 4. Acromegaly - DelveInsights Analytical Perspective. 4.1. In-depth Commercial Assessment. 4.1.1. Acromegaly companies collaborations, Licensing, Acquisition -Deal Value Trends. 4.1.1.1. Assessment Summary. 4.1.2. Acromegaly Collaboration Deals. 4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis. 4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis. 4.1.2.3. Acromegaly Acquisition Analysis. 5. Therapeutic Assessment. 5.1. Clinical Assessment of Pipeline Drugs 5.1.1. Assessment by Phase of Development. 5.1.2. Assessment by Product Type (Mono / Combination). 5.1.2.1. Assessment by Stage and Product Type. 5.1.3. Assessment by Route of ...
Request for sample pages. Table of contents. 1. Report Introduction. 2. Acromegaly 2.1. Overview. 2.2. History 2.3. Acromegaly Symptoms. 2.4. Causes. 2.5.Pathophysiology. 2.6. Acromegaly Diagnosis 2.6.1. Diagnostic Guidelines. 3. Acromegaly Current Treatment Patterns. 3.1. Acromegaly Treatment Guidelines. 4. Acromegaly - DelveInsights Analytical Perspective. 4.1. In-depth Commercial Assessment. 4.1.1. Acromegaly companies collaborations, Licensing, Acquisition -Deal Value Trends. 4.1.1.1. Assessment Summary. 4.1.2. Acromegaly Collaboration Deals. 4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis. 4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis. 4.1.2.3. Acromegaly Acquisition Analysis. 5. Therapeutic Assessment. 5.1. Clinical Assessment of Pipeline Drugs 5.1.1. Assessment by Phase of Development. 5.1.2. Assessment by Product Type (Mono / Combination). 5.1.2.1. Assessment by Stage and Product Type. 5.1.3. Assessment by Route of ...
Request for sample pages. Table of contents. 1. Report Introduction. 2. Acromegaly 2.1. Overview. 2.2. History 2.3. Acromegaly Symptoms. 2.4. Causes. 2.5.Pathophysiology. 2.6. Acromegaly Diagnosis 2.6.1. Diagnostic Guidelines. 3. Acromegaly Current Treatment Patterns. 3.1. Acromegaly Treatment Guidelines. 4. Acromegaly - DelveInsights Analytical Perspective. 4.1. In-depth Commercial Assessment. 4.1.1. Acromegaly companies collaborations, Licensing, Acquisition -Deal Value Trends. 4.1.1.1. Assessment Summary. 4.1.2. Acromegaly Collaboration Deals. 4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis. 4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis. 4.1.2.3. Acromegaly Acquisition Analysis. 5. Therapeutic Assessment. 5.1. Clinical Assessment of Pipeline Drugs 5.1.1. Assessment by Phase of Development. 5.1.2. Assessment by Product Type (Mono / Combination). 5.1.2.1. Assessment by Stage and Product Type. 5.1.3. Assessment by Route of ...
Request for sample pages. Table of contents. 1. Report Introduction. 2. Acromegaly 2.1. Overview. 2.2. History 2.3. Acromegaly Symptoms. 2.4. Causes. 2.5.Pathophysiology. 2.6. Acromegaly Diagnosis 2.6.1. Diagnostic Guidelines. 3. Acromegaly Current Treatment Patterns. 3.1. Acromegaly Treatment Guidelines. 4. Acromegaly - DelveInsights Analytical Perspective. 4.1. In-depth Commercial Assessment. 4.1.1. Acromegaly companies collaborations, Licensing, Acquisition -Deal Value Trends. 4.1.1.1. Assessment Summary. 4.1.2. Acromegaly Collaboration Deals. 4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis. 4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis. 4.1.2.3. Acromegaly Acquisition Analysis. 5. Therapeutic Assessment. 5.1. Clinical Assessment of Pipeline Drugs 5.1.1. Assessment by Phase of Development. 5.1.2. Assessment by Product Type (Mono / Combination). 5.1.2.1. Assessment by Stage and Product Type. 5.1.3. Assessment by Route of ...
Introduction: The prevalence of erectile dysfunction (ED) and its correlates in men with acromegaly has never been investigated. This study was aimed at evaluating sexual function in men with acromegaly.Methods: Multicenter-based, retrospective analysis of a non-selected series of 57 acromegalic subjects (52.7±14.2 years). Acromegalic subjects reporting ED (n=24) were compared with matched ED-patients without acromegaly or pituitary disease (controls), selected from a cohort of more than 4000 subjects enrolled in the Florence Unit. Patients were interviewed using SIEDY structured interview, a 13-item tool for the assessment of ED-related morbidities. Several clinical and biochemical parameters were taken. Penile colour-Doppler ultrasound (PCDU) was performed in a subgroup of 37 acromegalic subjects. Results: ED was reported by 42.1% of acromegalic subjects. After adjusting for age and testosterone, acromegalic subjects with ED had a higher prevalence of hypertension, and more often reported an ...
increase in Turkish saddle sizes and destruction of its walls, which allows not only to establish the presence of a tumor and its size, but also to identify the data on tumor growth direction.Lack sella change does not exclude the presence of a small pituitary adenomas and acromegaly.The increase in Turkish saddle at Statistics Team of acromegaly is diagnosed in 80-93% of patients, including 145 patients - at 137, but only 68% according to other patients.. great diagnostic value also have other radiological signs of acromegaly, in particular changes in the spine.. Just as in the diagnosis of hormonally inactive pituitary tumors, the diagnosis of acromegaly is very important ophthalmologic research, especially the dynamic monitoring of changes in visual fields.Has revealed bitemporal hemianopsia half of patients with acromegaly.. biochemical and hormonal studies play a small role in the diagnosis of acromegaly.A known value in the diagnosis of acromegaly in the active phase is defined as the ...
acromegaly - MedHelps acromegaly Center for Information, Symptoms, Resources, Treatments and Tools for acromegaly. Find acromegaly information, treatments for acromegaly and acromegaly symptoms.
Acromegaly is a hormonal disorder that is caused by the presence of excessive levels of the Growth Hormone (GH) in the body. The symptoms of acromegaly are enlargement of the bones of hands, forehead, jaws, feet and nose, which results in joint pain, thicker skin, headaches and vision problems. Complications in severe acromegaly may include type 2 diabetes, sleep apnea and elevated blood pressure. Acromegaly is generally caused when the pituitary gland produces greater levels of GI than the body normally requires, which is mostly caused by benign tumour or pituitary adenoma.. The global acromegaly treatment market is fragmented resulting in high pressure on pricing with numerous players dotting the scene. Vendors are engaged in new product developments, especially biologics. However, improvements in distribution efficiency is the need of the hour as strategic partnerships between market players and hospitals is expected to accelerate the uptake of acromegaly treatment. Technology gains from ...
Acromegaly is associated with higher morbidity and mortality mainly due to cardiovascular disease. Data on the incidence and evolution of thyroid cancer in acromegaly are controversial. Our objective was to describe the characteristics of a group of acromegalic patients with differentiated thyroid carcinoma (DTC) and analyze their evolution. This is a retrospective multicenter study of 24 acromegalic patients with DTC. The AJCC Staging System 8th Edition was used for TNM staging, and the initial risk of recurrence (RR), initial response and response at the end of follow-up (RFU) were defined according to the 2015 ATA Guidelines. As a control group, 92 patients with DTC without acromegaly were randomly included. Statistical analyses were done using SPSS Statistics 20.0. Median age of patients at diagnosis of acromegaly was 49.5 years (range 12-69). The median delay in diagnosis of acromegaly was 3 years (range 0.5-23). Mean baseline IGF-1 level was 2.9 ± 1.1 ULN. Median age at DTC diagnosis was 51.5
TY - JOUR. T1 - Plasma growth hormone response to thyrotropin releasing hormone in patients with active acromegaly. AU - Faglia, G.. AU - Beck-Peccoz, P.. AU - Ferrari, C.. AU - Travaglini, P.. AU - Ambrosi, B.. AU - Spada, A.. PY - 1973. Y1 - 1973. N2 - Out of 21 patients with active acromegaly, 12 increased plasma GH concentration after TRH injection (200 μg iv). No correlation was found between basal plasma GH levels, plasma GH response to hypoglycemia, arginine, oral glucose load and plasma GH response to TRH. The plasma GH peak often preceded that of TSH. One patient TSH unresponsive to TRH and 2 patients poorly responsive to TRH showed a rise in plasma GH. In 1 patient who increased both TSH and GH after TRH, the plasma response was abolished by triiodothyronine administration, while that of plasma GH remained unchanged. Since it was demonstrated that a releasing hormone acts activating the adenylcyclase system after binding to specific cellular receptors, it is suggested that in some ...
A hyperfunctioning growth hormone - secreting pituitary adenoma is the most common cause of acromegaly. Rarer causes are ectopic or hypothalamic growth hormone releasing hormone-secreting tumor. Since the signs and symptoms of acromegaly are indolent, the time from onset of signs and symptoms to diagnosis of acromegaly is long, usually taking years. The pituitary adenomas that cause growth hormone excess are usually large and are easily identified on routine MRI imaging of the sella. Treatment would then involve resection of the pituitary adenoma via transsphenoidal surgery. In rare cases, a pituitary MRI may show negative results. A contrast enhanced CT scan of the chest and abdomen is the next step to detect ectopic sources of GH or GH releasing hormone (GHRH) production. Acromegaly without imaging evidence of a pituitary macroadenoma or an ectopic source is very rare. Lonser et al., reported 6 patients (mean age 56 years) with signs, symptoms and biochemical evidence of acromegaly without ...
UK sufferers of the super-rare disease acromegaly are to be united for the first time ever to share their experiences in a special conference in Birmingham on the 1st of July.. Acromegaly is caused by excessive release of growth hormones from a benign tumour in the pituitary gland underneath the brain.. Symptoms are enlarged hands and feet, change in facial appearance, visual impairment, enlargement of organs (including the heart) and more.. In some cases acromegaly (called gigantism in youth) can cause huge growth spurts.. Famous sufferers include Andre the Giant, James Bond star Richard Kiel and Robert Wadlow, the tallest man ever.. Acromegaly is thought to affect just 50-70 people per million.. Dan Jeffries, an acromegaly survivor and author who is organising the event said, It can take years until you discover you have acromegaly, and the impact on your life can be huge - it will be emotional to get everyone together for the first time.. We normally use social media to support each other ...
Acromegaly ACROMEGALY Acromegaly is caused by GH secretion usually from a macroadenoma. Etiology- Pituitary adenoma Extrapituitary tumour GHRH- mediated acromegaly is most common cause is abdominal carcinoid tumour. Clinical features- Excessive GH secretion Before closure of epiphyses- tall stature & gigantism After closure of epiphysis- acromegaly Prognathism Nasal sinus enlargement Increased heel pad thickness Widened space between lower incisor teeth & defect in mandible Enlargement of hands & feet Carpel tunnel syndrome Osteoarthritis Hyperhidrosis Muscle hypertrophy Cardiomegaly, macroglossia & thyroid gland enlargement Diabetes mellitus Investigations- Screening- random serum IGF- 1 elevated Oral glucose tolerance test with GH measure confirms acromegaly Prolactin elevated Treatment- Surgical- Trans- sphenoidal surgery- first line of treatment Radiotherapy is the second line of treatment. Drugs- somatostatin ananlogues (lanreotide)- lowers GH levels Dopamine agonist (Cabergoline) Exam Important
TY - JOUR. T1 - The impact of diabetes mellitus on the survival of patients with acromegaly. AU - Wen-Ko, Chiou. AU - Szu-Ta, Chen. AU - Feng-Hsuan, Liu. AU - Chen-Nen, Chang. AU - Ming-Hsu, Wang. AU - Jen-Der, Lin. PY - 2016/1/1. Y1 - 2016/1/1. N2 - Introduction: An increased risk of mortality in patients with uncontrolled acromegaly has been reported in several studies. We aimed to assess the impact of co-morbidities on the survival of patients with acromegaly after long-term treatment and follow-up. Materials and methods: A retrospective analysis was performed for 285 patients with active acromegaly, who were admitted to the Chang Gung Memorial Hospital, Taiwan between 1978 and 2012. Of these patients, 106 (37.2%) were diagnosed with diabetes mellitus (DM). During the follow-up period, 21 cases of histological proved malignant in acromegalic patients, and DM with acromegaly had a higher incidence of malignancy (13.2% vs. 3.8%; p , 0.01). The 5-, 10-, and 20-year survival rates were 93.1%, ...
Acromegaly is associated with a variety of cardiovascular disturbances such as left ventricular hypertrophy, diastolic cardiac dysfunction, and hypertension. Left ventricular (LV) dyssynchrony means the impairment of synchronicity and is defined as the loss of the simultaneous peak contraction of corresponding cardiac segments. The objective of this study was to investigate whether acromegalic patients have left ventricular dyssynchrony. Dyssynchrony was evaluated in 30 patients with active acromegaly and 30 controls. All the patients and controls were subjected to a tissue synchronization imaging. The time to regional peak systolic tissue velocity (Ts) in LV by the six-basal-six-mid-segmental model was measured on ejection phase TSI images and four TSI parameters of systolic dyssynchrony were computed. All TSI parameters of LV dyssynchrony increased in patients with acromegaly compared to the controls: the standard deviation (SD) of the 12 LV segments Ts (43.5 +/- A 13.5 vs 26.2 +/- A 12.5, p < ...
Objective: Acromegaly is a rare pituitary disease due to excessive secretion of GH. Insulin resistance, impaired glucose tolerance (IGT) and diabetes mellitus (DM) are common features in acromegaly. Seventy-four active acromegalic patients were retrospectively evaluated in order to determine the impact of family history for diabetes mellitus on glucose tolerance, insulin resistance and beta-cell function.. Patients and methods: We studied 74 patients with active acromegaly (mean IGF-1 value: 576.8±35.6 ng/ml ES; mean GH value on OGTT nadir 11.8±1.8 ng/ml ES), 29 males and 45 females, aged 50.4±14.1 years, body mass index (BMI) 28.1±4.3 (kg/m2). All patients underwent an oral glucose tolerance test (OGTT): GH, blood glucose and insulin were sampled at 0, 30, 60, 90, 120 minutes. Insulin resistance was evaluated with HOMA2-IR, Quicki and ISI0.120; beta cell function was evaluated with HOMA2%-ß index.. Results: Acromegalic patients with a positive family history for diabetes mellitus showed an ...
A link between progressive dental malocclusion, the use of a continuous positive airway pressure mask and GH-secreting pituitary macroadenoma (acromegaly) has not been previously reported. The present clinicopathological analysis stresses that tooth malposition should not be seen exclusively as a local process. A 62-year-old caucasian man with no relevant medical history reported difficulty chewing food and perceived voice alteration during his annual periodontal check-up. He also referred stiffness of the tongue, face, and submandibular area. The patient had been diagnosed with obstructive sleep apnea syndrome two years previously, since when he had worn a continuous positive airway pressure device during sleep. Exploration of the occlusion revealed significant changes: an atypical left lateral and anterior open bite with major buccoversion of teeth 33, 34, 35, 36. Inspection of the soft tissue revealed only macroglossia, although external palpation indicated a subcutaneous stiffness of the
Growth Hormone-Secreting Pituitary Adenoma: A pituitary tumor that secretes GROWTH HORMONE. In humans, excess HUMAN GROWTH HORMONE leads to ACROMEGALY.
In this paper, we have described a high prevalence of DM and ECMDs in patients with acromegaly. Over 50% of our patients had DM, either overt and already being treated with diet or medication or diagnosed with an OGTT during our study. In a further 26% of subjects, the OGTT revealed the presence of IFG or IGT, together named ECMDs. The prevalence of both DM and ECMDs was significantly higher in patients with acromegaly than in the general population or in a population with a high risk of diabetes; only 22% of subjects with acromegaly were normoglycaemic. This report on glucose metabolism derangements in a large population of patients with acromegaly in Russia confirms earlier reports demonstrating the prevalence of ECMDs to be higher in these patients than in the general population (2, 5, 6, 7).. In accordance with these earlier observations, we observed those patients who had already developed diabetes or ECMDs to be older and have a higher BMI, and a longer duration of acromegaly. In addition, ...
Acromegaly Support is an online community resource committed to raising awareness of the early signs and symptoms of acromegaly and creating a safe space for those affected by this rare condition to share their experiences.. Visit our acromegaly community resources page for our partnering organizations joined together to combat stigmas surrounding acromegaly, promote early diagnosis, and push for optimal treatment and care for all patients with acromegaly worldwide.. ...
Hello acromegaly friends and families, We have lots to share with Ottawa Acromegaly Awareness and Support Network. President Dianne Sauvé and myself (Heather Elder, VP) recently attended the 2019 International Acromegaly Conference, held March 20-22 in New Orleans. This incredible event allowed us to meet over 200 individuals connected to the acromegaly community-patients from around…
Our current committee is: Co-Chair: Catherine Chan [email protected]: Clark McPhillips [email protected]: Fay Partington [email protected]: Wayne Holtham [email protected] Officer: Alison Chester [email protected]
TY - JOUR. T1 - Validity and clinical applicability of the acromegaly quality of life questionnaire, AcroQoL: A 6-month prospective study. AU - Webb, Susan M.. AU - Badia, Xavier. AU - Surinach, Nuria Lara. AU - Astorga, R.. AU - Benito, P.. AU - Catalá, M.. AU - Gaztambide, S.. AU - Gilabert, M.. AU - Gómez, J. M.. AU - Halperin, I.. AU - Lucas, A.. AU - Lucas-Morante, T.. AU - Moreno, B.. AU - de Pablos, P.. AU - Páramo, C.. AU - Picó, A.. AU - Roset, M.. AU - Torres, E.. AU - Varela, C.. PY - 2006/8/1. Y1 - 2006/8/1. N2 - Objective: Validate the acromegaly quality of life (AcroQoL) questionnaire as a disease-generated questionnaire, which analyses physical and psychological domains, the latter subdivided into appearance and personal relationship sub-scales, to evaluate health-related quality of life (HRQoL) in acromegaly. Design: Prospective, observational multicenter study. Methods: One hundred and six patients with acromegaly, 42 with active disease studied basally and 6 months after ...
Somatotroph pituitary adenoma is the most frequent cause of acromegaly. A transsphenoidal removal of the tumor is used as the first line treatment. Somatostatin analogs are used as to whether recovery was not obtained after surgery or pituitary surgery was contraindicated. Previous studies with somatostatin analogs have shown a drop in plasma GH and IGF-1 levels and a reduction in adenoma size in 75 and 25% of patients respectively. Retrospective studies suggest that a treatment with somatostatin analogs performed before surgery may be of interest to improve anesthesic conditions and surgical outcome. The aim of present study is to prospectively evaluate the interest of a first line treatment with a long-acting somatostatin analog (Sandostatin) before performing a pituitary surgery in acromegalic patients with either a micro or a macroadenoma to improve peri-operative conditions and hopefully surgical outcome. After informed consent, untreated acromegalic patients will be included and randomly ...
Lonser R, Kindzelski BA, Mehta GU, Jane JA Jr., Oldfield EH. Acromegaly without imaging evidence of pituitary adenoma. J Clin Endocrinol Metab. 2010;95(9):4192-6. PMCID: PMC2936064. https://doi.org/10.1210/jc.2010-0570.. Khandelwal D, Khadgawat R, Mukund A, Suri A. Acromegaly with no pituitary adenoma and no evidence of ectopic source. Indian J Endocrinol Metab. 2011;15(Suppl 3):S250-2. PMCID: PMC3183531. https://doi.org/10.4103/2230-8210.84878.. Katznelson L, Laws E, Melmed S, et al. Acromegaly: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(11):3933-51. PMID: 25356808. https://doi.org/10.1210/jc.2014-2700.. Mercado M, Borges F, Bouterfa H, et al. A prospective, multicenter study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf). 2007;66(6):859-68. PMID: 17465997. PMCID: PMC1974838. ...
To study the effect of chronic excess growth hormone on adipose tissue, we performed RNA sequencing in adipose tissue biopsies from patients with acromegaly (n = 7) or non-functioning pituitary adenomas (n = 11). The patients underwent clinical and metabolic profiling including assessment of HOMA-IR. Explants of adipose tissue were assayed ex vivo for lipolysis and ceramide levels. Patients with acromegaly had higher glucose, higher insulin levels and higher HOMA-IR score. We observed several previously reported transcriptional changes (IGF1, IGFBP3, CISH, SOCS2) that are known to be induced by GH/IGF-1 in liver but are also induced in adipose tissue. We also identified several novel transcriptional changes, some of which may be important for GH/IGF responses (PTPN3 and PTPN4) and the effects of acromegaly on growth and proliferation. Several differentially expressed transcripts may be important in GH/IGF-1-induced metabolic changes. Specifically, induction of LPL, ABHD5, and NRIP1 can ...
The literature on an association between acromegaly and cancer is particularly abundant on either colorectal cancer or thyroid cancer, and an endless debate is ongoing whether patients with acromegaly should be submitted to specific oncology screening and surveillance protocols. The aim of the present work is to review the more most recent data on the risk of either colorectal cancer or thyroid cancer in acromegaly and discuss the opportunity for specific screening in relation to the ...
Acromegaly is a rare disease commonly caused by a GH secreting pituitary adenoma, frequently a macroadenoma (>1cm) [3]. The management ofacromegaly should be always dedicated to improve the quality of life, signs and symptoms of the disease. The cure in acromegaly is mainly biochemical, indicated by normalization of GH below 2.5ug/L, GH suppression to 1ug/L during an Oral Glucose Tolerance Test (OGTT) and IGF-1 level normalization for age and gender [1]. In some cases, despite of establishing the cure of the disease, recurrence or persistence is possible.. Transspenoidal microsurgery has been demonstrated to be an effective way to treat acromegalic patients, however rates of cure with surgery alone have been reported only to 60% [4]. Thus at least 40% of patient will be diagnosed with either persistent disease or recurrence [1,4], and will require further medical or surgical intervention.. This particular patient presented as recurrent acromegaly after 18 years initial surgical treatment, with ...
en] Familial acromegaly is an exceptional clinical entity when not associated with features of multiple endocrine neoplasia type 1 (MEN1). We report here 3 pedigrees in each of which 2 patients have been shown to develop acromegaly. In 4 patients, clinical follow-up, and biological screening allowed to confidently exclude MEN1. Absence of mutation in the MEN1 gene after direct DNA analysis in 2 pedigrees reinforces the conviction that the families do not have MEN1. In families 1 and 2, diagnosis was made at a very early age and voluminous adenomas with suprasellar expansion were already present at the time of diagnosis. We review the 20 previous reports of familial acromegaly, some of them questionable. Our 3 families, combined with some other published pedigrees, allow the delineation of a familial form of acromegaly, distinct from MEN1. Dominant inheritance with reduced, age-dependant penetrance is the most parsimonious model to explain the recurrences. Gs protein pathway could be the site of ...
PURPOSE:. Early diagnosis is a success factor for the prevention of long-term comorbidity and premature death in patients with acromegaly, but large-scale data on the diagnostic process and disease management are scarce. Therefore, we aimed to evaluate the diagnostic process, implementation of treatment and changes in life situation in patients with acromegaly, focusing on sex-specific differences.. METHODS:. Non-interventional patient-reported outcome study. 165 patients with clinically and biochemically proven acromegaly were questioned about the diagnostic process and utilization of health care by means of a self-developed standardized postal survey including questions on acromegaly symptoms experienced before diagnosis, number and specialty of consulted doctors, time to diagnosis and aftercare.. RESULTS:. The diagnostic process took 2.9 (SD 4.53) years, during which 3.4 (SD 2.99) physicians were consulted. Women waited longer [4.1 (SD 5.53) years] than men [1.6 (SD 2.69) years; p = 0.001] ...
Acromegaly: Definition and history, causes, signs and symptoms of acromegaly. Treatment, radiotherapy, and homeopathic medicines for acromegaly treatment.
Acromegaly is known to be associated with insulin resistance. Visceral adipose tissue is increased in patients with insulin resistance and we aimed to investigate a visceral adipose tissue content as a possible marker of insulin resistance in diabetic and nondiabetic acromegalic patients. We compared 16 diabetic and 16 nondiabetic acromegalic patients for fasting blood glucose (FBG), insulin and visceral adipose tissue content calculated from abdominal computer tomography. All patients were active acromegalic. Diabetic patients were well controlled with diet alone or diet and oral antidiabetic drugs. Diabetic patients were significantly older than nondiabetics(51.94±10.17 vs 41.38±13.43 years, P=0.018). GH and IGF-1 levels were similar in both groups. Visceral adipose tissue content did not differ between diabetic and nondiabetic patients. Age, GH, IGF-1, FBG and fasting insulin were not correlated with adipose tissue content. In conclusion, concomittant well controlled diabetes might not ...
A 56-years-old woman was referred to our unit for partially treated acromegaly. She had a high level of insulin growth factor. She did not complain of any pulmonary symptoms and was a non-smoker. Physical examination revealed clinical features of acromegaly. She had a 13 mm pituitary adenoma and was proposed for surgical intervention. Her chest X-ray showed a right paracardiac tumor. Computed tomography scan revealed a large right-sided fowler tumor. Pituitary surgery was cancelled and lobectomy after biopsy with lymph nodes excision was performed through thoracotomy. Histological study of the tumor revealed a medium differentiated epidermoid carcinoma with positive lymph nodes and extension to pleura. She was referred to chemotherapy protocol. Association between carcinoma and acromegaly has previously been reported. Most common tumors are colorectal and thyroid neoplasia. As we see in this case report, we need to consider other carcinomas in acromegalic patients like pulmonary carcinoma, despite their
Basel, September 26, 2014 - The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Signifor® (pasireotide) long acting release (LAR) formulation to treat adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with a first-generation somatostatin analogue (SSA)[2]. If approved in the EU, this next-generation SSA could fill a current unmet need, providing a new therapeutic option for the approximately 45% of acromegaly patients whose growth hormone (GH) or insulin-like growth factor-1 (IGF-1) levels remain inadequately controlled despite treatment with currently available SSAs[2],[3].. Affecting an estimated one to two patients per 10,000 people in the EU, acromegaly is a rare, debilitating endocrine disorder caused by the excess production of GH and IGF-1[1],[4]. The disease is caused by a non-cancerous tumor in the pituitary gland[1]. ...
TY - JOUR. T1 - Arthropathy in acromegaly. T2 - a questionnaire-based estimation of motor disability and its relation with quality of life and work productivity. AU - Study Group on Motor Disability in Acromegaly of the Italian Society of Endocrinology. AU - Fatti, L M. AU - Cangiano, B. AU - Vitale, G. AU - Persani, L. AU - Mantovani, G. AU - Sala, E. AU - Arosio, M. AU - Maffei, P. AU - Dassie, F. AU - Mormando, M. AU - Giampietro, A. AU - Tanda, L. AU - Masiello, E R. AU - Nazzari, E. AU - Ferone, D. AU - Corbetta, S. AU - Passeri, E. AU - Guaraldi, F. AU - Grottoli, S. AU - Cannavò, S. AU - Torre, M L T. AU - Soranna, D. AU - Zambon, A. AU - Cavagnini, F. AU - Scacchi, M. PY - 2019/10. Y1 - 2019/10. N2 - PURPOSE: Arthropathy is a common and disabling complication of acromegaly. Since in this condition radiological findings rarely correspond to functional impairment, we elected to quantify in a large cohort of acromegalic patients: the degree of motor disability compared with data from ...
In patients who do not achieve biochemical remission by surgery, options for adjunctive therapy include medical therapy and radiation therapy. There are three types of medical therapy that can be offered. 1. Somatostatin Analogs The most commonly used class of medications used to treat acromegaly are somatostatin analogs. These long-acting analogs of the endogenous inhibitor of GH, somatostatin, will suppress GH and thereby lower circulating IGF-I levels. In most patients, they retard tumor growth, and some patients have significant tumor shrinkage. Complete biochemical remission occurs in 20% to 60% of patients. Somatostatin analogs work by activating somatostatin receptors on the tumor cells, but variability in the expression and density of the specific receptor subtypes activated by these analogs results in variable patient responses. Three analogs are clinically available: octreotide LAR (long-acting release), lanreotide autogel, and pasireotide LAR. These are given as intramuscular ...
OBJECTIVE: To evaluate the effectiveness of the treatment of acromegaly patients at the Federal University of Triangulo Mineiro. METHODS: Cross-sectional and retrospective study of thirty cases treated over a period of two decades. RESULTS: 17 men (56.7%) aged 14-67 years and 13 women aged 14-86 years were analyzed. Twenty-one patients underwent transphenoidal surgery, whichwas associated with somatostatin receptor ligands in 11 patients (39.3%), somatostatin receptor ligands + radiotherapyin 5 patients (17.8%), radiotherapy in 3 patients (10.7%), and radiotherapy + somatostatin receptorligands + cabergoline in 1 patient (3.6%). Additionally, 2 patients underwent radiotherapy and surgeryalone. Six patients received somatostatin receptor ligands before surgery, and 2 were not treated due to refusal and death. Nine patients have died, and 20 are being followed; 13 (65%) have growth hormonelevels o1 ng/mL, and 11 have normal insulin-like growth factor 1 levels. CONCLUSION: The current treatment
VetVine is an accredited Continuing Education provider for veterinary professionals and resource of expert-driven pet health information for pet owners. This is the forum topic view page. Feline acromegaly (hypersomatropism or HST) is a spontaneously occurring condition caused by a growth hormone (GH) secreting pituitary tumor (somatotrophinoma). Studies estimate 1 in 3 to 1 in 5 diabetic cats have acromegaly (HST)-induced diabetes mellitius.  Cats with high levels of growth hormone exhibit insulin resistance, arthropathy, general abdominal organ enlargement, and cardiovascular disease. Diabetic cats affected by acromegaly are frequently difficult to control with insulin alone, and controlling glucose levels will not manage other aspects of the disease.  In humans with HST, treatment options include surgical removal of the pituitary tumor, radiation treatment and medical treatment. One form of medical treatment is the use of somatostatin analogs, the drug form of choice in most patients. To
FDA Approval for Enzymatic Hemoglobin A1c Assay Kit. When insulin is not NPH and PZI and various Please note that some insulin formulations require refrigeration and others Diabeteksen hoidon osaamiskeskuksia on aikuisin diabeteksen hoito toteutuisi psntisesti perusterveydenhuollon hyvinvointikeskuksissa joiksi Oulu (which can contribute to high blood pressure). Diabetes And Chicken Nuggets Mellitus Prevalence Acromegaly Patients can Coffee Bean Extract Help The green coffee [extract] To say that something can prevent or delay diabetes is almost impossible to prove unless Paul Carlyle Diabetes Miracle Cure Program Review under a cold shower will stimulate your Cure Program Review: Miracle Diabetes Cure Guide Suspected Drug Lab Discovered after Flash Fire Injures Man Near Downtown Detailing the Dangers of Chicken Jerky.. If your fasting is consistently above 95 or your post eating Continuing Education for Pharmacists Diabetes Education: This list of continuing education activities is provided ...
Radiating the Tumor details my experiences living with acromegaly. The journey begins where the tumor regains its strength, working to take over a second time.. Within the posts I share my attempts to find peace of mind, to heal and my hopes for remission. I detail my thoughts and feelings throughout stereotactic radiation treatments. And continue as, well, one does in life.. Originally diagnosed with acromegaly due to a hormone producing pituitary macro-adenoma in early 2014, in May of 2014 I underwent transsphenoidal surgery at Johns Hopkins Hospital in Baltimore, Maryland.. I was at the beginning, and I remain today, committed to fighting for peace of mind free from the pains of acromegaly. I am determined that this rare disease will not claim me as its victim.. For more information, kindly complete the contact form below. Wishing you and yours the very best.. Copyright © 2017 . All rights reserved.. ...
ICD-10 Code: E22.0. Definition: Acromegaly is caused by overproduction of growth hormone, most commonly by a benign pituitary tumor (pituitary adenoma). Acromegaly may be accompanied by distinct findings in the musculoskeletal system that may contribute to early detection and diagnosis.. Cardinal Findings: Excess growth hormone causes acromegaly in adults and, if the onset is before epiphyseal closure, gigantism in children. Clinically, patients develop distinctive coarse facial features; thickening of the skin; enlarged mandible, hands, and feet; prominent forehead and supraorbital ridging; enlarged tongue and enlarged viscera; hirsutism; oily skin; and excessive sweating. The musculoskeletal complaints result from premature osteoarthritis, kyphosis of the spine, pseudogout, entrapment neuropathies [e.g., carpal tunnel syndrome (CTS)]. Many patients complain of nonspecific arthralgias affecting the shoulder, knees, hips, and spine.. Complications: Increased cardiovascular morbidity and ...
Address all correspondence and requests for reprints to: J. O. L. Jørgensen, Medical Department M, Aarhus University Hospital, Norrebrogade 44, DK-8000 C Aarhus, Denmark. E-mail: [email protected] .. Context: Pegvisomant is a GH receptor antagonist that blocksthe peripheral actions of GH in acromegaly. Pegvisomant, incontrast to somatostatin (SMS) analogs, does not suppress theactivity of the GH-producing adenoma.. Objective: We assessed the effects of cotreatment with pegvisomantand SMS in acromegaly on GH secretion, IGF-I levels, and glucosetolerance.. Design, Patients, and Interventions: Eleven patients with persistentdisease despite previous therapy underwent the following fixedtreatment algorithm: 1) on SMS therapy, 2) off therapy for 2months, 3) 6-wk treatment with 10 mg/d pegvisomant, 4) 6-wktreatment with 15 mg/d pegvisomant, and 5) 3-month treatmentwith 15 mg pegvisomant plus SMS. Blood was sampled in the fastingstate and during an oral glucose tolerance test.. Results: Total serum IGF-I ...
Acromegaly may be treated with hormone-suppressing drugs or with radiation to shrink a pituitary tumor, but it is most often treated surgically, by neurosurgeons and otolaryngological (ENT) surgeons. Removing the pituitary tumor is usually a cure for acromegaly. (More about Pituitary and Skull Base Surgery at Weill Cornell.) The neurosurgeons at Weill Cornell who treat acromegaly and the pituitary tumors that cause it are:
OBJECTIVE: Acromegaly is associated with long-term adverse effects on cardiovascular mortality and morbidity. Reducing growth hormone secretion improves well-being and symptoms, but may not significantly improve the lipoprotein profile. An additional approach to cardiovascular risk reduction in acromegaly may therefore be to target lipoprotein metabolism directly. In this study we investigated the effect of statin treatment. DESIGN: Double blind, placebo-controlled, crossover study of the effects on circulating lipoproteins of atorvastatin 10 mg daily vs. placebo. Each treatment was given for 3 months in random order. SUBJECTS: Eleven patients with acromegaly. MEASUREMENTS: Lipids, lipoproteins, apolipoproteins, enzyme activity and calculated cardiovascular risk. RESULTS: Atorvastatin treatment compared to placebo resulted in a significant decrease in serum cholesterol (5.85 +/- 1.04 mmol/l vs. 4.22 +/- 0.69 mmol/l; mean +/- SD; P | 0.001), low-density lipoprotein (LDL) cholesterol (2.95 +/- 1.07 mmol/l
Despite availability of multiple treatment modalities, acromegaly sometimes is a challenging condition to treat, and we report a patient whose disease was only controlled with pasireotide. The patient had a sparsely granulated tumour with suprasellar extension and invasion of the cavernous sinus, and these tumours are known to be more difficult to control. Sparsely granulated somatotroph adenomas are commoner among young females, are generally larger than densely granulated somatotroph adenomas, less responsive to somatostatin receptor ligands (1, 2) and more frequently reported to have suprasellar extension and cavernous sinus infiltration (3).. A number of factors in our patient are associated with increased resistance to treatment of acromegaly. Preoperative GH levels are an important predictor of remission in acromegaly (4). Extremely high disease burden is indicated by clinical findings, biochemistry and imaging and could have contributed largely to the poor response to initial treatment in ...
Acromegaly is a hormonal disorder that results from the pituitary gland producing too much growth hormone (GH). It is most often diagnosed in middle-aged adults, although symptoms can appear at any age. Signs and symptoms include abnormal growth and swelling of the hands and feet; bone changes that alter various facial features; arthritis; carpal tunnel syndrome; enlargement of body organs; and various other symptoms. The condition is usually caused by benign tumors on the pituitary called adenomas. Rarely, it is caused by tumors of the pancreas, lungs, and other parts of the brain. Acromegaly is usually treatable but when left untreated, it can result in serious illness and premature death. When GH-producing tumors occur in childhood, the disease that results is called gigantism rather than acromegaly ...
Insulin-like growth factor-1 (IGF-1) and growth hormone (GH) levels are the main targets for monitoring acromegaly activity, but they are not in close relationship with the clinical course of the disease and the associated comorbidities. The present study was aimed at identifying metabolites that could be used as biomarkers for a better disease phenotyping. For this purpose, metabolic fingerprint using an untargeted metabolomic approach was examined in serum from 30 patients with acromegaly and 30 age-matched controls. Patients with acromegaly presented fewer branched-chain amino acids (BCAAs) compared to the control group (valine: 4.75 ± 0.87 vs. 5.20 ± 1.06 arbitrary units (AUs), p , 0.05; isoleucine: 2.54 ± 0.41 vs. 2.80 ± 0.51 AUs; p , 0.05). BCAAs were also lower in patients with active disease compared to patients with normal levels of IGF-1 with or without medical treatment. GH, but not IGF-1, serum levels were inversely correlated with both valine and isoleucine. These findings ...
Clinical trial for Acromegaly , Safety Tolerability and Efficacy of IONIS-GHR-LRx in Patients With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands
AIM AND METHOD: Insulin resistance leading, in some cases, to glucose intolerance is an important contributory factor to the cardiovascular morbidity and mortality associated with acromegaly. The aim of this study was to document changes in insulin sensitivity (IS) in a group of seven patients with acromegaly (three male, four female, mean+/-s.d. age 59+/-13 Years) treated initially with a stable dose of depot octreotide (OT; median dose 30 mg four times weekly, range 10-30 mg) for a median of 18 Months (range 16-19 Months) and who were then transferred to treatment with pegvisomant (median dose 15 mg daily, range 10-20 mg) for a median of 8 Months (range 7-9 Months). IS was assessed by homeostatic model assessment (HOMA) using fasting glucose and insulin concentrations and by a short insulin tolerance test (sITT). Body composition was assessed by dual energy X-ray absorptiometry. RESULTS: Mean+/-s.d. serum IGF-I concentrations during therapy with OT and with pegvisomant were not statistically ...
Surgery to remove the pituitary tumor that is causing this condition often corrects the abnormal GH. Sometimes, the tumor is too large to be removed completely and acromegaly is not cured. In this case, medicines and radiation (radiotherapy) may be used to treat acromegaly. Some people with tumors that are too complicated to remove by surgery are treated with medicines instead of surgery. After treatment, you will need to see your provider regularly to make sure that the pituitary gland is working normally and that acromegaly does not come back. Yearly evaluations are recommended. ...